Disease Progression

The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.

Also Known As:

Networked: 63038 relevant articles (3428 outcomes, 7280 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Infections
3.	Breast Neoplasms (Breast Cancer)
4.	COVID-19
5.	Inflammation (Inflammations)

Experts

1.	Zhang, Li: 65 articles (01/2022 - 08/2005)
2.	Li, Wei: 62 articles (12/2022 - 08/2005)
3.	Nakagawa, Kazuhiko: 52 articles (04/2022 - 12/2008)
4.	Zhang, Wei: 50 articles (06/2022 - 04/2005)
5.	Zetterberg, Henrik: 49 articles (05/2022 - 12/2011)
6.	Alzheimer’s Disease Neuroimaging Initiative: 48 articles (10/2022 - 01/2012)
7.	Reck, Martin: 47 articles (04/2022 - 10/2005)
8.	Alzheimer's Disease Neuroimaging Initiative: 47 articles (01/2022 - 01/2009)
9.	Pazdur, Richard: 44 articles (11/2022 - 01/2002)
10.	Wang, Yan: 43 articles (07/2022 - 08/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Disease Progression:

1.	Biomarkers (Surrogate Marker)IBA 01/01/2019 - "These diseases could be more effectively treated and prevented if RCS-related biomarkers were identified and measured at an early stage of disease progression, which makes development of a point of care test (POCT) platform extremely desirable for early diagnosis. " 01/01/2019 - "Preclinical models more reflective of human pathophysiology, identification of biomarkers to predict severity of disease progression, and improved design of clinical trials may more rapidly advance the opportunities in this important field." 01/01/2023 - "Alterations in FC may be an important mechanism underlying the neurodegenerative process in patients with asymptomatic MCA steno-occlusive disease before structural changes occur, so FC assessment may promote the detection of network alterations, which may be used as a biomarker of disease progression and therapeutic efficacy evaluation in these patients." 01/01/2022 - "Since clinical course of this disease is largely unpredictable and can develop rapidly causing severe complications, it is important to identify laboratory biomarkers, which may help to classify patient's severity during initial stage. " 12/01/2019 - "Identifying biomarkers of CLN2 disease progression will be important in assessing the efficacy of therapeutic interventions for this disorder. "
2.	Adrenal Cortex Hormones (Corticosteroids)IBA 01/01/1990 - "The clinical course of the case was compatible with the typical phases described in the literature, and the condition underwent complete remission following treatment with corticoids." 06/01/2015 - "However, some studies suggest that low-dose corticosteroids for about 1-2 months (depending on clinical course) are beneficial in relieving acute rheumatic symptoms. " 09/01/2007 - "They showed that the two populations share the same clinical course; nevertheless they revealed the frequency of partial remission, failed treatment, relapses, necessity of high dose of corticosteroids, and difficulties of discontinuing treatment in PF. " 06/01/2016 - "Corticosteroid treatment has only been shown to accelerate resolution of the acute forms, but there is no evidence that it is effective in preventing disease progression in the long-term or reducing mortality. " 05/02/2006 - "Three trials reported improved time-to-disease progression, palliative response, and/or quality of life with mitoxatrone plus corticosteroid compared with corticosteroid alone. "
3.	VaccinesIBA 11/01/2006 - "The convergence of these observations suggests that vaccines designed to focus immune responses narrowly against regions of HIV susceptible to highly deleterious mutations might prove effective in controlling viral replication to levels that slow disease progression and reduce transmission. " 12/01/2022 - "Despite a vaccine that is successful in preventing COVID-19-caused death, effective medication to relieve COVID-19-associated symptoms and alleviate disease progression is still in high demand. " 01/24/2015 - "Only one candidate vaccine has significantly reduced HIV-1 acquisition, yet at a limited efficacy of 31%, and none have delayed disease progression in vaccinated individuals. " 01/01/2000 - "The IFN-alpha-based vaccine has showed a significant reduction of disease progression in IFN-alpha-vaccine-treated HIV-infected patients. " 03/27/2023 - "Elucidating the infectious cofactors that impact on pathogenesis may open doors for the design of new potential therapeutic strategies to control disease progression, especially in contexts where vaccines or the sterile clearance of pathogens are not effectively available."
4.	SteroidsIBA 01/01/2022 - "Achieving a sustained clinical remission off steroids with complete endoscopic remission in this cohort of 95 patients with early CD was not associated with less disease progression. " 10/01/2016 - "Disease activity in the year after diagnosis appears to be a good predictor of future disease activity as about two-third of the patients who remain in remission tend to remain unchanged thereafter, whereas those patients treated with steroids have, manifestly, an unfavourable subsequent clinical course. " 06/01/2009 - "Continuous low-dose steroids are necessary to maintain remission, significantly reducing the risk of disease progression." 01/01/2012 - "In this preliminary study, mTPE appeared safe and may bring about improvement in disability and sustained stabilization of the clinical course in patients with steroid-refractory relapsing forms of NMO." 09/01/2003 - "The other patient has a somewhat milder clinical course and considerable improvement could be accomplished with moderate and low doses of steroids. "
5.	Antiviral Agents (Antivirals)IBA 01/01/1999 - "These findings, combined with the introduction of potent new antivirals (15,16), have stimulated a growing interest in viral load monitoring, both as a function of disease status, and as a predictor of disease progression and therapeutic efficacy." 01/01/1999 - "These findings, combined with the introduction of potent new antivirals (15,16), have stimulated a growing interest in viral load monitoring, both as a function of disease status, and as a predictor of disease progression and therapeutic efficacy." 11/14/2022 - "In this real-life setting, the early use of both of the oral antivirals helped limit composite outcome at 30 days among subjects who were at high risk of disease progression." 08/15/2004 - "Measuring viral infectivity may thereby function as an additional, useful marker in monitoring disease progression and evaluating efficacy of antivirals in vivo." 12/01/2014 - "Tim-3 blockade leads to improved antiviral CD8(+) T cell responses in vitro and, therefore, represents a novel intervention strategy to restore T cell function in vivo and protect from disease progression. "
6.	Anti-Bacterial Agents (Antibiotics)IBA 09/21/2005 - "In both studies, patients generally received 2 weeks of antibiotics and had multiple sequential follow-up endoscopic examinations until complete histologic remission (CR) or disease progression; patients were monitored through January 31, 2004. " 06/01/2011 - "A urethral catheterization and administration of antibiotics resulted in the marked improvement in the clinical course. " 07/01/2016 - "The proportions of the Actinomyces species remained stable in the antibiotic group but showed a statistically significant reduction in the control group from 1 to 2 y in subjects achieving a low risk clinical profile for future disease progression (i.e., ≤4 sites with probing depth [PD] ≥5 mm). " 11/01/2003 - "These results suggest that successful management might be improved by addressing factors contributing to disease progression during sterilization of the cornea by antibiotics." 03/21/1997 - "The clinical course, documented by the APACHE II score, showed significant improvement under antibiotic treatment (days 1-5-10: scores 15-13.0-9.5). "
7.	Bevacizumab (Avastin)FDA Link 03/01/2009 - "Intravitreal bevacizumab application provides significant improvement in visual acuity of diabetic patients and clinical course of macular oedema, and may therefore be a promising approach in the primary treatment of diabetic macular oedema." 02/13/2023 - "Although the PFS was generally similar to that reported in other studies, the OS was shorter, probably due to the less frequent use of bevacizumab after disease progression and the baseline patient characteristics. " 01/01/2022 - "In all studies, CT (induction or maintenance with FP) + anti-EGFR until disease progression or unacceptable toxicity prolonged OS (HR = 0.72 [95%CI 0.61-0.86]; P < .01) and PFS (HR = 0.76, 95%CI 0.68-0.85; P < .01) compared to other agents (FP ± bevacizumab) or observation. " 09/01/2017 - "Patients who continued bevacizumab beyond disease progression did not have clear survival improvements, although the study was not powered to detect other than very large differences. " 01/01/2017 - "Since bevacizumab was administered as standard treatment until disease progression, the importance of bevacizumab during the maintenance phase was not prospectively investigated in these studies. "
8.	Proteins (Proteins, Gene)FDA Link 01/01/2019 - "Studies of synaptic protein changes may improve the understanding of disease mechanisms and provide valuable markers of disease progression and therapeutic efficacy. " 01/01/2018 - "These studies provide mechanistic insights into how NRG signaling on microglia may lead to disease progression and demonstrate the utility of a humanized fusion protein that blocks NRG as a novel therapeutic for human ALS." 01/01/2022 - "Proteins that might affect disease progression and therapeutic efficacy of hUCB-MSC were identified through LC-MS/MS analysis using serum samples. " 08/01/2006 - "If so, the correlation of clinical parameters with defined protein expression patterns would allow us to predict disease progression and perhaps even postulate improved therapeutic modalities. " 01/01/2020 - "Evidence in cells and in vivo demonstrates promising results in many disease models, in which autophagy upregulation is able to reduce the levels of toxic proteins, ameliorate signs of disease, and delay disease progression. "
9.	CytokinesIBA 04/01/2014 - "Disease progression is associated with aberrant cytokine expression, and TNF blockade is the most successful therapy to date. " 11/01/2023 - "To conclude, miR-155 negatively regulates TLR-mediated cytokines as wel l as the expression of host restriction factors, which play an important role in mounting anti-HIV responses; hence, targeting miR-155 might be helpful in devising strategic approaches towards alleviating HIV disease progression." 06/01/2016 - "Accordingly, in human studies, a decrease of pro-inflammatory and an increase of anti-inflammatory cytokines have been measured and a significant reduction of disease progression and a decrease in brain volume loss has been demonstrated. " 08/01/2022 - "Identifying nutritional interventions and dietary patterns that improve the inflammatory cytokine profile, and therefore disease progression and inflammatory comorbidities of RA will help further focus research on treatments that may provide a better overall improvement in quality of life for RA patients by focusing on the root cause inflammatory processes that affect not only joint destruction but also depression-rated disability. " 01/01/2022 - "Amongst human studies, Perrilyl alcohol, derived from Lavender, reduced angiogenic cytokines in 31% of subjects, halted 6 month disease progression in 48.2% of subjects, and improved mean survival by 4.9 months in separate studies, respectively. "
10.	PlatinumIBA 07/24/2014 - "Patients with high RRM1 expression benefited more from a platinum-containing regimen, and patients with high BRCA1 expression showed a high response rate to a platinum-containing regimen and reduced disease progression. " 01/01/2016 - "Although a majority of patients respond to a platinum-containing regimen, many fail to respond to first-line treatment (platinum-refractory disease) or experience disease progression within 6 months of completing treatment (platinum-resistant disease). " 09/15/2009 - "Patients with UC were eligible if they received a prior platinum-based regimen in the neoadjuvant/adjuvant setting or as first-line treatment for advanced/metastatic disease and had developed disease progression within 12 months. " 01/01/2015 - "The results from the current study, for the first time to our knowledge, provide suggestive evidence of an effect of TERT polymorphisms on disease progression variability among Chinese patients with platinum-treated advanced NSCLC." 04/20/2009 - "The aim of this study is to compare the toxic effects, disease progression time and overall survival time between advanced NSCLC patients 60 or older than 60 and younger than 60 who are administrated with palitaxel plus platinum-based agents. "

Therapies and Procedures

1.	Therapeutics 01/01/2022 - "This study represents the most extensive collection of prospective, instrumental swallowing assessments in NPC1 to date with an interpretive analysis providing an improved understanding of NPC1 disease progression with swallowing function-serving as a foundation for clinical management and future NPC1 therapeutics." 12/01/2021 - "By reviewing the most recent common mental health disorders (CMHD) studies in people living with HIV (PLWH) (2018-2020), this review discusses the prevalence of CMHD, factors associated with CMHD in PLWH, mental health in PLWH from vulnerable groups, the impact of CMHD on HIV disease progression and adherence to antiretroviral therapy and the efficacy of different treatment approaches. " 01/01/2022 - "Many factors need to be considered when deciding on the best treatment strategy for PD, such as disease progression, presence of risk factors for motor and behavioral complications, potential side effects from dopaminergic therapy and phenotypical variabilities. " 01/01/2022 - "A real challenge in OA management is the lack of an effective cure because exiting therapeutics often provide symptom control rather than disease modification; therefore, they fail to prevent disease progression. " 01/01/2021 - "Unfortunately, most patients will experience disease progression and thus an urgent need exists for improved subsequent lines of therapies. "
2.	Drug Therapy (Chemotherapy) 01/01/2020 - "Improved intensive chemotherapy regimens have influenced the clinical course of the disease, with late relapses now being less frequent and the brain having overtaken bone as the most common site of relapse." 01/01/2017 - "Cluster analyses suggested that the cisplatin+fluorouracil-based chemotherapy regimen had the best short-term efficacy for EGJA in terms of the complete response (CR), PR, ORR, stable disease (SD) and progression disease (PD). " 12/12/2022 - "Before January 1, 2019, the treatment was mainly chemotherapy, and 10 patients were initially treated with chemotherapy, among whom was one patient who progressed during initial treatment, was voluntarily discharged and was subsequently lost to follow-up, one patient who died of disease progression, and the remaining 8 patients who all achieved sustained remission, with a complete remission (CR) rate of 80% (8/10). " 08/01/2020 - "The clinical course of FL-LP could be aggressive, but a significant proportion of the patients obtained complete remission with chemotherapy." 04/01/2017 - "Further analysis revealed that patients with the disease controlled [complete response (CR) + partial response (PR) + stable disease (SD)], no matter whether they received first-or second-line chemotherapy, may have had an improved OS compared with patients with disease progression (PD). "
3.	Radiotherapy 04/30/2022 - "Although, some patients with limited disease can be cured with radiation therapy alone, most patients experience disease progression and recurrence during follow-up despite early initiation of treatment. " 06/01/2014 - "Only radiotherapy (XRT) has proven to be effective in delaying the disease progression. " 01/01/2016 - "Radiotherapy (RT) immediately after RP may potentially eradicate any residual localized microscopic disease in the prostate bed, and it is associated with improved biochemical, clinical progression-free survival, and overall survival in patients with high-risk pathological features according to published randomized trials. " 12/01/1996 - "Analysis of the recurrence and survival rates demonstrated that radiotherapy did not confer any significant protection against recurrence or disease progression. " 08/01/1972 - "All of these tumours tend to have a short clinical course, although survival time seems to be significantly improved by surgical excision followed by radiotherapy. "
4.	Immunotherapy 01/01/2022 - "Specific unmet needs continue to exist for patients who develop disease progression after concurrent chemoradiation and immunotherapy, as well as defining the best treatment for patients with driver mutations. " 06/01/2020 - "However, our case showed the very benign clinical course and improved rapidly without any immunotherapy. " 01/01/1988 - "After immunotherapy, one patient entered complete remission, four patients had stationary disease, and six had marked clinical progression. " 01/01/2020 - "In conclusion, our study reveals for the first time that the TIGIT/DNAM-1 axis may be involved in Foxp3+ γδ Treg cells and indicates the clinical progression and prognosis of AML patients of different clinical statuses, which is considered beneficial for efficient AML immunotherapy." 08/01/1992 - "At the present time, data remain limited, but three controlled studies have found statistically significant reductions in the rate of disease progression, and one has found a significant reduction in the mortality rate, with BCG immunotherapy. "
5.	Aftercare (After-Treatment) 06/01/2021 - "After treatment, 11 patients had complete remission (CR), 3 had partial remission (PR), 1 had stable disease (SD), and 6 had disease progression (PD). " 10/05/2016 - "After treatment, 3 patients with complete remission(CR), 14 patients with partial response(PR),2 patients in stable condition, and 1 patient with progression disease. " 01/01/2019 - "Other than 1 patient who died of disease progression, 15 patients (93.8%) achieved complete remission (CR) after treatment, although 5 (33.3%) relapsed. " 01/01/2019 - "Three untreated patients had a rapid, lethal clinical course within 7 months after diagnosis; while, the remaining three achieved complete remission after treatment and were alive at the last follow-up. " 01/01/2016 - "Pooled hazard ratios between responders and non-responders, as determined by rCBV, were 0.46 (95 % CI 0.28-0.76) for progression-free survival from five articles with a total 226 patients and 0.47 (95 % CI 0.29-0.76) for overall survival from six articles with a total 247 patients, and thus indicating that rCBV is helpful for predicting disease progression and the eventual outcome after treatment. "